Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CYBN vs BHST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CYBN Captures Overall Composite Edge (63.8 BUY vs 58.2 HOLD), While BHST Leads 4–2 on Growth & Valuation Pillars

CYBN Overall Winner 6-Pillar Tally: CYBN 2 – 4 BHST Matrix Metrics: CYBN 7 – 1 BHST

As of Nov 20, 2026, Cybin Inc. (CYBN) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (63.8/100 BUY vs. 58.2/100 HOLD) after splitting the core matrix 7–1 (led by Profitability & Quality, Options & Positioning), while BHST wins 4–2 across the 6-pillar growth and valuation breakdown. CYBN trades at $8.28 (N/M Forward P/E, 0.0% operating margin) versus BHST at $1.30 (N/M Forward P/E, -18.0% operating margin).

  • Growth vs. Quality Trade-Off: CYBN earns the overall head-to-head edge with a stronger Unified Composite Score (63.8/100 BUY vs. BHST 58.2/100 HOLD) and 1.50β · 54% Vol risk profile, whereas BHST leads top-line expansion (+3.8% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CYBN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 69.8); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CYBN vs BHST
CYBN NYSE American Head-to-Head Winner
Cybin Inc.
Pharmaceutical Preparations
$8.28
+1.22% 1D
Market Cap $413.4M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.50β · 54% Vol
Unified Composite Score
63.8 / 100 BUY
Tech 75.0 Fund 66.0 Flow 58.0 Mom 70.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.6% over 20 days), RSI 70
RSI-14: 69.8 · SMA20: $7.10 · SMA50: $6.57
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
TTM Revenue $35M
Forward P/E N/M
Beta / 30D Vol 0.25β · 86% Vol
Unified Composite Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 37
RSI-14: 37.2 · SMA20: $1.55 · SMA50: $1.58

6-Pillar Scorecard Institutional Category Breakdown (CYBN 2 – 4 BHST)

Columns: Metric · CYBN · BHST
1. Valuation Multiples BHST
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 0.7x
2. Growth & Scale BHST
Revenue Growth (YoY) +0.0% +3.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $35M
Market Cap $413.4M $29.9M
3. Profitability & Quality CYBN
Gross Margin N/A 59.0%
Operating Margin 0.0% -18.0%
Net Profit Margin 0.0% -31.2%
Return on Equity (ROE) -53.0% -142.5%
4. Balance Sheet & Cash Flow BHST
Cash Generation (TTM) N/A -$9.4M
Cash Flow Margin N/A -26.6%
Net Cash / Leverage $5.33 Book/Sh · -53.0% ROE $5.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CYBN
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 169.0% (100th %ile) N/A (N/A)
Put/Call OI Skew 0.13x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BHST
OpEx & R&D Intensity N/A 77.0% of Rev ($27M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Packaged Foods Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CYBN (7) vs BHST (1)
Institutional Metric CYBN BHST Criterion Row Edge
Market Capitalization
Scale
$413.4M $29.9M Larger Scale CYBN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +3.8% Higher Growth BHST
Operating Margin (TTM)
Profitability
0.0% -18.0% Higher Margin CYBN
Net Profit Margin
Profitability
0.0% -31.2% Higher Margin CYBN
Return on Equity (ROE)
Capital Efficiency
-53.0% -142.5% Higher ROE CYBN
52-Week Range Position
Momentum
59% ($5–$11) 6% ($1–$7) Stronger Trend CYBN
Beta / 30D Volatility
Risk Regime
1.50β · 54% Vol 0.25β · 86% Vol Lower Realized Risk CYBN
Unified Institutional Score
Composite Signal
63.8 / 100 (BUY) 58.2 / 100 (HOLD) Higher Composite CYBN
Trailing 12M Revenue (USD)
Operating Scale
N/A $35M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 59.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($5.33 Book/Sh · -53.0% ROE) -$9.4M ($5.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CYBN +67.96 pp
CYBN: +50.27% · BHST: -17.69%
3M Horizon CYBN +57.06 pp
CYBN: +39.63% · BHST: -17.43%
6M Horizon CYBN +57.06 pp
CYBN: +39.63% · BHST: -17.43%
1Y Horizon CYBN +57.06 pp
CYBN: +39.63% · BHST: -17.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CYBN vs BHST. Trailing 12-month operating profitability (CYBN 0.0% vs BHST -18.0%) and valuation multiples (CYBN N/M vs BHST N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CYBN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-53.0% · N/M
BHST ADR TTM Benchmark FX-Normalized USD
TTM Revenue$35M
Gross Margin59.0%
Op. Margin-18.0%
ROE / Fwd P/E-142.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CYBN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 169.0%
IV Percentile 100th %ile
Put/Call OI Skew 0.13x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CYBN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BHST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BHST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CYBN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $413.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BHST Moat Profile Cyclical / Execution-Driven Positioning
Packaged Foods Operator
Competes within the Packaged Foods value chain with $29.9M market capitalization and -18.0% operating margin.
OpEx & R&D Reinvestment 77.0% of Rev ($27M)
90D Engineering Disclosures 0 Published

Investor FAQ CYBN vs BHST Key Questions & Quantitative Answers

As of Nov 20, 2026, Cybin Inc. (CYBN) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (63.8/100 BUY vs. 58.2/100 HOLD) after splitting the core matrix 7–1 (led by Profitability & Quality, Options & Positioning), while BHST wins 4–2 across the 6-pillar growth and valuation breakdown. CYBN trades at $8.28 (N/M Forward P/E, 0.0% operating margin) versus BHST at $1.30 (N/M Forward P/E, -18.0% operating margin). Growth vs. Quality Trade-Off: CYBN earns the overall head-to-head edge with a stronger Unified Composite Score (63.8/100 BUY vs. BHST 58.2/100 HOLD) and 1.50β · 54% Vol risk profile, whereas BHST leads top-line expansion (+3.8% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CYBN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 69.8); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BHST leads the Growth & Scale pillar: CYBN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with BHST at +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin). On trailing 12-month operating scale, CYBN generates N/A in USD-normalized revenue versus $35M for BHST. In operating R&D and SG&A reinvestment, CYBN deploys N/A (0 90-day corporate R&D disclosures) versus 77.0% of Rev ($27M) (0 disclosures) for BHST.

BHST screens cheaper on headline valuation multiples. CYBN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CYBN (-53.0% ROE) versus BHST (-142.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CYBN carries 169.0% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.50β · 54% Vol realized risk). By comparison, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.